Compare Citius Pharmaceuticals Inc (CTXR) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs FMC Corp — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while FMC Corp trades at $8.3 (market cap $1.39B). The key difference: FMC Corp is far larger — about 102.1× Citius Pharmaceuticals Inc's market cap, and FMC Corp pays a 3.59% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and FMC Corp for 68 Days on average.
| CTXR | FMC | |
|---|---|---|
Market Cap | $13.62M | $1.39B |
Volume | 132,438 | 4,145,979 |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $30.63 |
52-Week Low | $0.48 | $8.44 |
Typical Hold Time | 17 Days | 68 Days |
Enterprise Value | $3.79M | $5.19B |
Dividend Yield | — | 3.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
FMC trades at $8.36, down 8.03% in the past 24 hours, reflecting bearish technical signals and weak profitability. The company reported a net loss of -$2.24B in 2025, with negative margins and declining revenue. Recent news includes a regulatory filing for rimisoxafen in Brazil and a minority equity investment by Tessenderlo Group. Cash flow trends show volatility, with 2025 net cash flow positive at $227M but driven by financing activities.
The outlook remains challenging due to persistent losses and high debt, though analyst consensus suggests upside with a $14.60 price target. Key risks include execution on deleveraging, cyclical industry pressures, and competitive threats. Investment opportunity hinges on successful turnaround efforts and new product approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
